UNC, Kerr Drug to Study PGx Program for Plavix | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Drug store chain Kerr Drug and the Eshelman School of Pharmacy at the University of North Carolina, Chapel Hill plan to investigate the feasibility of implementing a pharmacogenomic program at the community pharmacy level directed at Plavix (clopidogrel).

Under the six-month study announced today, the partners will jointly develop a protocol, evaluate physician and patients opinions, and research reimbursement challenges and regulatory requirements to such a program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.